PĂdureanu Rodica, Albu Carmen Valeria, PĂdureanu Vlad, BugĂ Ana Maria
Department of Biochemistry, University of Medicine and Pharmacy of Craiova, Romania.
Department of Neurology, University of Medicine and Pharmacy of Craiova, Romania.
Curr Health Sci J. 2020 Oct-Dec;46(4):371-378. doi: 10.12865/CHSJ.46.04.07. Epub 2020 Dec 31.
Multiple Sclerosis (MS) is a multifactorial demyelinating diseases that affect mostly the young and active people. Here, is crucial to identify new strategies in order to slow down the diseases progression and maintain a good functional outcome. Our hypothesis was that the interconnection between anti-oxidant molecules and anti-inflammatory or neuroprotective molecules can act as predictors of diseases progression. In the study were included 36 patients with MS. Inclusion criteria were the following: patients over 18 years old were divided in three groups, 16 relapsing-remitting MS (RRMS) group, 10 secondary progressive MS (SPMS) group and 10 healthy control group. We showed that the vitamin D sufficiency did not improve de EDSS score in the later stage of diseases. Also, we showed that in the early stage (RRMS) the vitamin D status can significantly improve the EDSS and IADL score and may slow down the diseases progression. started with the early stage of diseases (RRMS) we found that catalase activity, an enzyme that act as anti-oxidant, is significantly decreased compare with healthy people, and can be associated with a low level of vitamin D. we concluded that a pro-oxidative and anti-oxidative balance is an important player in the multifactorial mechanism of MS diseases progression and additional prospective studies are needed to determine optimal vitamin D levels that lead to clinical and immunological benefits for patients with MS. Long-term follow-up studies using high-dose vitamin D supplementation are needed to confirm the preliminary results of the studies.
多发性硬化症（MS）是一种多因素导致的脱髓鞘疾病，主要影响年轻且活跃的人群。在此，识别新策略以减缓疾病进展并维持良好的功能结局至关重要。我们的假设是抗氧化分子与抗炎或神经保护分子之间的相互联系可作为疾病进展的预测指标。该研究纳入了36例MS患者。纳入标准如下：18岁以上的患者分为三组，16例复发缓解型MS（RRMS）组、10例继发进展型MS（SPMS）组和10例健康对照组。我们发现维生素D充足在疾病后期并未改善扩展残疾状态量表（EDSS）评分。此外，我们还表明在疾病早期（RRMS），维生素D状态可显著改善EDSS和日常生活活动能力量表（IADL）评分，并可能减缓疾病进展。从疾病早期（RRMS）开始，我们发现过氧化氢酶活性（一种作为抗氧化剂的酶）与健康人相比显著降低，且可能与低水平的维生素D有关。我们得出结论，氧化应激与抗氧化平衡在MS疾病进展的多因素机制中起着重要作用，需要进一步的前瞻性研究来确定能为MS患者带来临床和免疫学益处的最佳维生素D水平。需要进行长期的高剂量维生素D补充随访研究以证实这些研究的初步结果。
